GALAFOLD (migalastat hydrochloride) by Amicus Therapeutics is alpha-galactosidase a (alpha-gal a) protein (encoded by the galactosidase alpha gene, gla ), which is deficient in fabry disease. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
GALAFOLD (migalastat hydrochloride) is an oral small-molecule chaperone that treats Fabry disease by stabilizing deficient alpha-galactosidase A protein, enabling it to traffic to lysosomes and break down accumulated glycosphingolipids. It is indicated for patients with amenable GLA gene variants—specific mutations where the enzyme retains partial activity but is misfolded. This precision-medicine approach requires genetic testing to identify which patients will respond.
Product is at peak commercial performance with modest Medicare uptake (~1,121 claims in 2023); brand team likely stable in size but focused on market penetration within eligible patient population.
alpha-galactosidase A (alpha-Gal A) protein (encoded by the galactosidase alpha gene, GLA ), which is deficient in Fabry disease. This binding stabilizes alpha-Gal A allowing its trafficking from the endoplasmic reticulum into the lysosome where it exerts its action. In the lysosome, at a lower pH…
Worked on GALAFOLD at Amicus Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Patients With Fabry Disease (US Specific)
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moGALAFOLD careers center on rare-disease expertise, genetic variant identification, and payer/provider education rather than high-volume commercial execution. Roles emphasize precision-medicine logistics, patient finder programs, and long-term patient relationships typical of orphan pharma, offering niche specialization but limited headcount growth.